Cepheid (CPHD) : Champlain Investment Partners scooped up 222,960 additional shares in Cepheid during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 3,436,980 shares of Cepheid which is valued at $122,803,295.Cepheid makes up approximately 2.01% of Champlain Investment Partners’s portfolio.
Other Hedge Funds, Including , Nuveen Asset Management reduced its stake in CPHD by selling 18,372 shares or 24.06% in the most recent quarter. The Hedge Fund company now holds 57,992 shares of CPHD which is valued at $2,072,054. Cepheid makes up approx 0.01% of Nuveen Asset Management’s portfolio. Bessemer Group Inc sold out all of its stake in CPHD during the most recent quarter. The investment firm sold 660 shares of CPHD which is valued $23,582.Ubs Asset Management Americas Inc boosted its stake in CPHD in the latest quarter, The investment management firm added 779,199 additional shares and now holds a total of 991,633 shares of Cepheid which is valued at $35,440,963. Cepheid makes up approx 0.04% of Ubs Asset Management Americas Inc’s portfolio. Essex Investment Management Co sold out all of its stake in CPHD during the most recent quarter. The investment firm sold 6,601 shares of CPHD which is valued $218,493.Smith Asset Management Group Lp reduced its stake in CPHD by selling 210 shares or 1.27% in the most recent quarter. The Hedge Fund company now holds 16,310 shares of CPHD which is valued at $539,861. Cepheid makes up approx 0.02% of Smith Asset Management Group Lp’s portfolio.
Cepheid opened for trading at $34.97 and hit $35.435 on the upside on Monday, eventually ending the session at $35.07, with a gain of 0.40% or 0.14 points. The heightened volatility saw the trading volume jump to 3,28,175 shares. Company has a market cap of $2,560 M.
On the company’s financial health, Cepheid reported $0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.00. The company had revenue of $146.00 million for the quarter, compared to analysts expectations of $145.92 million. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.06 EPS.
Cepheid is a molecular diagnostics company. The Company develops manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps including sample preparation DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system which integrates sample preparation in addition to DNA amplification and detection serves reference laboratories and hospital central laboratories to satellite testing locations such as emergency departments and intensive care units within hospitals as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system which integrates DNA amplification and detection to allow rapid analysis of a sample.